Month: September 2026

SANTIAGO, Chile, Sept. 25, 2026 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Wednesday November 4, 2026, at 11.00 AM Chile time (9.00 AM ET) where we will discuss 3Q 2026 financial results. The Bank’s Officers participating in the conference call are: Patricia Pérez, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Andres Sansone, Chief Economist. A question and answer session will follow the presentation.

The Management Commentary report will be published on October 30, 2026, before the market opens. The quiet period begins on October 16.

To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987

Or please dial in using any of the below numbers:
United Kingdom +44 203 984 9844
USA +1 718 866 4614
Austria +43 720 022981
Brazil +556120171549
Canada +1 587 855 1318
Chile +56228401484
Czech Republic +420 910 880101
Estonia +372 609 4102
Finland +35 8753 26 4477
France +33 1758 50 878
Germany +49 30 25 555 323
Hong Kong +852 3001 6551
Mexico +52 55 1168 9973
Peru +51 1 7060950
Poland +48 22 124 49 59
Russia +7 495 283 98 58
Singapore +65 3138 6816
South Africa +27872500455
South Korea +82 70 4732 5006
Sweden +46 10 551 30 20
Turkey +90 850 390 7512
Ukraine +380 89 324 0624

Participant Passcode: 720987
Please dial in approximately 10 minutes prior to the starting time of the conference.

If you have any questions, please contact Cristian Vicuña at Banco Santander Chile at Cristian.vicuna@santander.cl, Rowena Lambert at Rowena.lambert@santander.cl or Claudia Villalon at claudia.villalon@santander.cl

CONTACT INFORMATION

Cristian Vicuña
Investor Relations
Banco Santander Chile
Bandera 140, Floor 20
Santiago, Chile
Email: irelations@santander.cl
Website: www.santander.cl

About Santander

Banco Santander Chile is one of the companies with the highest risk ratings in Latin America, with an A2 rating from Moody’s, A- from Standard & Poor’s, A+ from the Japan Credit Rating Agency, and AA- from HR Ratings. All ratings have a stable outlook as of the date of this report.

As of June 30, 2026, the Bank has total assets of CLP 70,323,331 million (US$ 76,348million), total gross loans (including loans owed by banks) at amortized cost of CLP 41,426,628 million (US$ 44,976 million), total deposits of CLP 32,390,791 million (US$ 35,166 million), and shareholders’ equity of CLP 4,974,214 million (US$ 5,400 million). The BIS capital ratio is 16.6%, with a core capital ratio of 11.1%. As of June 30, 2026, Santander Chile employs 8,315 people and has 224 branches throughout Chile.

Company to feature surgeon-led educational programming and technologies supporting liver surgery

PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, taking place September 26-29 in Washington, D.C. The company will feature surgeon-led educational programming focused on liver surgery, including presentations and clinical discussions featuring the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance® laparoscopic surgical instrumentation.

As part of ACS’s Innovation Theater programming, Integra LifeSciences will feature presentations from internationally recognized liver surgeons to share clinical perspectives and experience with approaches to complex liver procedures. With more than 800,000 people diagnosed with liver cancer worldwide each year¹, continued education and collaboration in liver surgery remain important for the treatment of patients with complex hepatobiliary conditions, including liver tumors.

Presenters include:

• Goro Honda, M.D., Ph.D., FACS, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
• Adnan Alseidi, M.D., M.Ed., M.B.A., FACS, professor of surgery, University of California, San Francisco (UCSF) and specialist in liver, pancreas and biliary surgery

“The ACS Congress provides an important opportunity to engage with the surgical community and exchange perspectives,” said Harvinder Singh, executive vice president and president, Specialty Surgery, Integra LifeSciences. “As we mark 20 years of CUSA within the Integra LifeSciences portfolio, we are proud of the role this technology plays in supporting surgeons globally. Integra LifeSciences remains focused on building upon proven technologies while addressing evolving clinical needs.”

Conference attendees are invited to visit Integra LifeSciences at Booth 428 and participate in the company’s Innovation Theater programming.

About CUSA® Clarity Ultrasonic Surgical Aspirator System

The CUSA Clarity Ultrasonic Surgical Aspirator System is indicated for use in surgical procedures where fragmentation, emulsification and aspiration of soft and hard (e.g. bone) tissue is desirable, such as neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery, cardiac surgery and liver resection and transplant surgery.

About MicroFrance® Laparoscopic Instruments

The MicroFrance® laparoscopic manual surgical instruments are intended for use in a wide variety of surgical procedures, including laparoscopic and endoscopic procedures. The instruments are intended to scrape, cut, grasp, hold, remove, or manipulate tissue or structures.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. These forward-looking statements include, but are not limited to, statements related to the potential applications and efficacy of the Integra LifeSciences products described herein and the realization of improvements to health outcomes. There can be no assurance that previously observed benefits will be replicated. The actual effect of the use of these products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will achieve or maintain commercial success. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra LifeSciences’ business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra LifeSciences’ Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra LifeSciences undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

_______________________
¹ American Cancer Society. Key Statistics About Liver Cancer. Updated Jan. 13, 2026. Accessed Sept. 23, 2026. American Cancer Society liver cancer statistics. [cancer.org]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/17d68748-4f8c-49e3-9da4-8f181ede652b

DENVER, Sept. 25, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — A completed library of living genetic building blocks positions Kraig Biocraft Laboratories (OTCQB: KBLB) to explore more than 200 potential configurations and pursue its ultimate goal of combining the full Atlas suite in one production strain.

Darwin’s bark spider offers a remarkable demonstration of what nature can engineer. Its silk ranks among the toughest natural fibers ever measured, with landmark research reporting roughly ten times the toughness of Kevlar a measure of how much energy a material can absorb before breaking. That extraordinary performance helps explain the enormous interest in turning spider silk biology into commercially useful materials.

It also provides context for a major development at Kraig Biocraft Laboratories.

According to the company’s release, Kraig has successfully integrated every planned Project Atlas transgene into living commercial silkworm hosts, completing its foundational Atlas Gene Library.

For readers following the company, the significance goes beyond the completion of a research collection. Kraig now has the full planned set of genetic building blocks inside living silkworms, establishing the foundation to combine those technologies and test what they can accomplish together.

The company says the library enables more than 200 potential genetic configurations. Its ultimate objective is to combine the full suite of Atlas genetics into a single production strain with advanced material properties.

Successfully completing that integration and demonstrating the intended performance could mark a historic milestone for Kraig and a significant advance in engineered biomaterials.

“Completing the Atlas Gene Library is a defining milestone for Project Atlas,” said Dr. Xiaoli Zhang, Kraig’s Chief Scientist. “Every planned Atlas transgene has now been established in commercial silkworm hosts, giving us the complete set of genetic building blocks we envisioned when Project Atlas began.”

The scale of the opportunity becomes clearer when considering how materials are used. An industrial fiber may need to withstand repeated stress. A protective textile may require energy absorption and flexibility. Different applications demand different combinations of properties.

Atlas is designed to pursue enhanced strength, toughness, and flexibility beyond Kraig’s current recombinant spider silk production line. Its genetic library could give researchers a way to explore multiple fiber designs and identify combinations suited to different performance requirements.

The Darwin’s bark spider comparison makes that ambition tangible. Nature has already demonstrated extraordinary silk performance. The engineering challenge is to translate that potential into useful fibers within a practical production system. Testing will establish the performance of Atlas-derived materials.

Kraig’s earlier work provides an important foundation for understanding the direction of the program. The company previously reported knock-in/knock-out gene-editing technology for producing nearly pure spider silk, demonstrating its ability to make targeted changes to silkworm silk genetics. That history provides context for Atlas’s broader ambition of bringing multiple advanced genetic technologies together in one strain.

The next stage is to establish stable homozygous breeding lines carrying matching copies of the relevant genetic insert. Those lines will provide the foundation for systematically assembling combinations and evaluating the resulting fibers.

For investors, this creates a concrete sequence of milestones to follow: stable breeding lines, successful genetic combinations, measured material performance, and selection of candidates for further commercial development.

The more than 200 configurations represent potential designs to investigate. Their value will emerge as researchers determine which combinations produce useful properties and can support reliable production.

Kraig says Atlas is advancing alongside its commercial spider silk production operations. That parallel development is central to the opportunity: better-performing materials need a manufacturing system capable of delivering them consistently.

With the Atlas Gene Library complete, Kraig has assembled the building blocks for its next major scientific push. The coming phases will test whether those components can work together to deliver a new generation of advanced fibers and how far the company can extend the commercial possibilities of engineered spider silk.

• Agnarsson, Kuntner & Blackledge (2010)—PLOS ONE
  The original study reported average silk toughness of approximately 350 MJ/m³, with some samples reaching 520 MJ/m³, and a comparison of more than ten times the toughness of Kevlar. This is the main source to link in the PR.
• Garb and colleagues (2019)—Communications Biology
  Examines the silk proteins that may contribute to this exceptional toughness and reiterates the tenfold Kevlar comparison, explaining the combination of strength and unusual stretchability.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.